Search Results

You are looking at 11 - 20 of 199 items for :

  • "Metastatic breast cancer" x
Clear All
Full access

Antonio Di Meglio, Nancy U. Lin, Rachel A. Freedman, William T. Barry, Eric P. Winer and Ines Vaz-Luis

Background Metastatic breast cancer (mBC) is a heterogeneous disease, with a multitude of treatment options available. 1 – 3 Monitoring patients with mBC with a combination of clinical, laboratory, and imaging evaluations allows for

Full access

Caijin Lin, Jiayi Wu, Shuning Ding, Chihwan Goh, Lisa Andriani, Shuangshuang Lu, Kunwei Shen and Li Zhu

with de novo metastatic breast cancer (MBC) is reported to be 12 to 32 months, suggesting that these patients constitute a heterogeneous group with a wide range of survival. 2 – 6 Consequently, it is not appropriate to assign these patients a “catch

Full access

Zeynep Eroglu, Odicie Fielder and George Somlo

treatment modifications. 17 Although the CellSearch system cutoff of 5 or greater CTCs per 7.5 mL of blood has been validated in metastatic breast cancer, isolation of a single cell (≥1 CTC per 7.5 mL of blood) has been considered the cutoff for CTC

Full access

Ingrid A. Mayer

). Genetic Profile of Resistance Genetic alterations are seldom seen in endocrine therapy-sensitive tumors but may be abundant in endocrine Figure 1 Treatment landscape for estrogen receptor–positive metastatic breast cancer. Abbreviations: AI

Full access

Erica L. Mayer, Nancy U. Lin and Harold J. Burstein

bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer [abstract] . J Clin Oncol 2005 ; 23 ( suppl 1 ): Abstract 7001 . 15. Cobleigh MA Langmuir VK Sledge GW . A phase I/II dose-escalation trial of bevacizumab in

Full access

Namratha Vontela, Vamsi Koduri, Lee S. Schwartzberg and Gregory A. Vidal

-breast radiation, she was maintained on adjuvant anastrozole (AI) until February 2013, when a PET/CT demonstrated metastatic bone-only disease; a biopsy confirmed metastatic breast cancer (mBC). Her therapy was then switched to fulvestrant and denosumab on April 4

Full access

Mohamed Ali Maher, Abdelhamid Mohamed Fouad and Mariam Maged Elhaddad

Context: The systemic treatment of metastatic breast cancer (MBC) prolongs survival and enhances quality of life but is not curative. Therefore, treatments associated with minimal toxicity are preferred. Thus, the use of the minimally toxic

Full access

Benigno Emmanuel Rodriguez Soto, Lorena López Zepeda, Alejandro Noguez Ramos, Daniela Vázquez Juarez, Daniela Shveid Gerson, Yazmin Carolina Blanco Vázquez, Samuel Rivera Rivera, Alberto Villalobos Prieto, Gabriela Olivia Regalado Porras, Ivonne Salcedo Sullk, Fernando Pérez Zincer, Christian Patricio Camacho Limas, Juan Alberto Serrano Olvera, Álvaro Aguayo González, Guillermo Manuel Olivares Beltrán and Raquel Gerson Cwilich

dependent kinase 4/6 inhibitor (CDK4/6i) to the hormonal treatment (HT) in metastatic breast cancer (MBC) increases the progression-free (PFS) and overall survival (OS) of these patients. Objective: Describe the use of CDK4/6i in patients with MBC with RH

Full access

Alison K. Conlin and Andrew D. Seidman

: a retrospective analysis based on individual patient data from six consecutive studies . Cancer 2005 ; 104 : 1742 – 1750 . 4. Carrick S Parker S Wilcken N . Single agent versus combination chemotherapy for metastatic breast cancer

Full access

Richard L. Theriault, Robert W. Carlson, Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead and Rashmi Kumar

highlight the important updates/changes specific to the management of HER2-positive metastatic breast cancer in the 2013 version of the NCCN Guidelines. These include clinical data and NCCN recommendations regarding the new therapeutic options, pertuzumab